Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 8, 2006, Pages 2851-2858

  Jiménez, Camilo ^a,b   Cote, Gilbert ^b   Arnold, Andrew ^c   Gagel, Robert F ^b  

^a Instituto Nacional de Cancerología   (Colombia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; VON HIPPEL LINDAU PROTEIN; IRON SULFUR PROTEIN; MEMBRANE PROTEIN; PROTEIN SUBUNIT; SDHB PROTEIN, HUMAN; SDHD PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE; VHL PROTEIN, HUMAN;

ANAMNESIS; GENE MUTATION; HUMAN; MEDICAL LITERATURE; MUTATION RATE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; ADULT; GENETICS; MUTATION; SYNDROME;

ADULT; GERM-LINE MUTATION; HUMANS; IRON-SULFUR PROTEINS; MEMBRANE PROTEINS; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN SUBUNITS; SUCCINATE DEHYDROGENASE; SYNDROME; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33747638645     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2178     Document Type: Article

References (102)

1. Wallace MR, Marchuk DA, Andersen LB 1990 Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186
2. Mulligan LM, Kwok JB, Healey CS 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
3. Latif F, Tory K, Gnarra J 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320
4. Niemann S, Muller U 2000 Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268-270
5. Baysal BE, Farr JE, Rubinstein WS 1997 Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23. Am J Hum Genet 60:121-132
6. Baysal BE, Ferrell RE, Willett-Brozick JE 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851
7. World Health Organization 2004 WHO classification of tumours: pathology and genetics of tumours of endocrine organs. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Lyon, France: IARC Press
8. Abell MR, Hart WR, Olson JR 1970 Tumors of the peripheral nervous system. Hum Pathol 1:503-551
9. Baysal BE 2002 Hereditary paraganglioma targets diverse paraganglia. J Med Genet 39:617-622
10. Brandi ML, Gagel RF, Angeli A 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
11. Maher ER 1994 Von Hippel-Lindau disease. Eur J Cancer 30A:1987-1990
12. Ruggieri M, Huson SM 1999 The neurofibromatoses: an overview. Ital J Neurol Sci 20:89-108
13. Baysal BE 2001 Genetics of familial paragangliomas: past, present, and future. Otolaryngol Clin North Am 34:863- 879, vi
14. Schussheim DH, Skarulis MC, Agarwal SK 2001 Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 12:173-178
15. Riccardi V 1992 Neurofibromatosis: phenotype, natural history, and pathogenesis. 2nd ed. Baltimore: Johns Hopkins University Press
16. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L 1997 Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125-2131
17. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM 1999 von Recklinghausen's disease and pheochromocytomas. J Urol 162:1582-1586
18. Chetty R, Duhig JD 1993 Bilateral pheochromocytoma-ganglioneuroma of the adrenal in type 1 neurofibromatosis. Am J Surg Pathol 17:837-841
19. Takehara K, Miyata Y, Matsuo M, Sakai H, Minami Y, Kanetake H 2001 [A case of malignant pheochromocytoma associated with von Recklinghausen's disease]. Hinyokika Kiyo 47:257-260 (Japanese)
20. Ogawa T, Mitsukawa T, Ishikawa T, Tamura K 1994 Familial pheochromocytoma associated with von Recklinghausen's disease. Intern Med 33:110-114
21. Gutmann DH, Aylsworth A, Carey JC 1997 The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57
22. Maher ER, Iselius L, Yates JR 1991 Von Hippel-Lindau disease: a genetic study. J Med Genet 28:443-447
23. Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG, Goldberg MA 1996 Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595-10599
24. Kamura T, Koepp DM, Conrad MN 1999 Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661
25. Hes FJ, Hoppener JW, Lips CJ 2003 Pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 88:969-974
26. Maxwell PH, Wiesener MS, Chang GW 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
27. Stebbins CE, Kaelin Jr WG, Pavletich NP 1999 Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455-461
28. Ohh M, Yauch RL, Lonergan KM 1998 The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959-968
29. Walther MM, Reiter R, Keiser HR 1999 Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162:659-664
30. Maher ER, Yates JR, Harries R 1990 Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151-1163
31. Maher ER, Webster AR, Richards FM 1996 Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 33:328-332
32. Richard S, Beigelman C, Duclos JM 1994 Pheochromocytoma as the first manifestation of von Hippel-Lindau disease. Surgery 116:1076-1081
33. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B 1995 von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 194:629-642
34. Eisenhofer G, Walther MM, Huynh TT 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86:1999-2008
35. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR 1999 Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879
36. Pujol P, Bringer J, Faurous P, Jaffiol C 1995 Metastatic phaeochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy. Eur J Nucl Med 22:382-384
37. Hofmockel G, Manseck A 2000 [Malignant pheochromocytoma combined with multiple renal cell carcinomas and a renal cyst. Indication for von Hippel-Lindau syndrome?]. Dtsch Med Wochenschr 125:767-768 (German)
38. Chen MY, Chew EY, Reynolds JC, Chao DL, Oldfield EH 2001 Metastatic brainstem pheochromocytoma in a patient with von Hippel-Lindau disease: case illustration. J Neurosurg 94:138
39. Mahoney EM, Harrison JH 1977 Malignant pheochromocytoma: clinical course and treatment. J Urol 118:225-229
40. Dackiw AP, Cote GJ, Fleming JB 1999 Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery 126:1097-1103; discussion 1103-1104
41. Carty SE, Helm AK, Amico JA 1998 The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124:1106-1113; discussion 1113-1114
42. Alberts WM, McMeekin JO, George JM 1980 Mixed multiple endocrine neoplasia syndromes. JAMA 244:1236-1237
43. Skogseid B, Rastad J, Gobl A 1995 Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 118:1077-1082
44. Burgess JR, Harle RA, Tucker P 1996 Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 131:699-702
45. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 281:1587-1588
46. Lips CJ, Minder WH, Leo JR, Alleman A, Hackeng WH 1978 Evidence of multicentric origin of the multiple endocrine neoplasia syndrome type 2a (Sipple's syndrome) in a large family in the Netherlands: diagnostic and therapeutic implications. Am J Med 64:569-578
47. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC 1996 Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120:1064-1070; discussion 1070-1071
48. Modigliani E, Vasen H, Raue K 1995 Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Int Med 238:363-367
49. Gagel RF, Tashjian Jr AH, Cummings T 1988 The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: an 18-year experience. N Engl J Med 318:478-484
50. Calmettes C, Rosenberg-Gourgin M, Caron J, Feingold N 1992 Pheochromocytoma: a frequent indicator for MEN 2. Henry Ford Hosp Med J 40:276-277
51. Eng C, Clayton D, Schuffenecker I 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 276:1575-1579
52. Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF 1999 A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes 13:77-79
53. Hofstra RM, Fattoruso O, Quadro L 1997 A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178
54. Jimenez C, Habra MA, Su-Chen EH, El-Naggar A, Shapiro S, Evans DB, Cote G, Gagel RF 2004 Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET proto-oncogene 891 germline mutation. J Clin Endocrinol Metab 89:4142-4145
55. Kouvaraki MA, Shapiro S, Perrier ND 2005 RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544
56. Pigny P, Bauters C, Wemeau JL 1999 A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84:1700-1704
57. Jimenez C, Dang G, Schultz P, Barnes E, Shapiro S, Evans D, El-Naggar A, Vassilopoulo-Sellin R, Gagel RF, Cote G, Hoff A 2004 A novel point mutation of the RET proto-oncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521-3526
58. Chevinsky AH, Minton JP, Falko JM 1990 Metastatic pheochromocytoma associated with multiple endocrine neoplasia syndrome type II. Arch Surg 125:935-938
59. Hinze R, Machens A, Schneider U, Holzhausen HJ, Dralle H, Rath FW 2000 Simultaneously occurring liver metastases of pheochromocytoma and medullary thyroid carcinoma: a diagnostic pitfall with clinical implications for patients with multiple endocrine neoplasia type 2a. Pathol Res Pract 196:477-481
60. 131I-meta-iodobenzylguanidine scintigraphy. Ann Nucl Med 6:111-115
61. Scopsi L, Castellani MR, Gullo M 1996 Malignant pheochromocytoma in multiple endocrine neoplasia type 2B syndrome: case report and review of the literature. Tumori 82:480-484
62. Westfried M, Mandel D, Alderete MN, Groopman J, Minkowitz S 1978 Sipple's syndrome with a malignant pheochromocytoma presenting as a pericardial effusion. Cardiology 63:305-311
63. Hamilton BP, Landsberg L, Levine RJ 1978 Measurement of urinary epinephrine in screening for pheochromocytoma in multiple endocrine neoplasia type II. Am J Med 65:1027-1032
64. Miyauchi A, Masuo K, Ogihara T 1982 Urinary epinephrine and norepinephrine excretion in patients with medullary thyroid carcinoma and their relatives. Nippon Naibunpi Gakkai Zasshi 58:1505-1516
65. Baysal BE, Willett-Brozick JE, Lawrence EC 2002 Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178-183
66. Gimm O, Armanios M, Dziema H, Neumann HP, Eng C 2000 Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 60:6822-6825
67. Neumann HP, Bausch B, McWhinney SR 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
68. Carney JA, Stratakis CA 2002 Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108:132-139
69. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA 2003 A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 3:193-202
70. Lopez-Barneo J, Pardal R, Ortega-Saenz P 2001 Cellular mechanism of oxygen sensing. Annu Rev Physiol 63:259-287
71. Taschner PE, Jansen JC, Baysal BE 2001 Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer 31:274-281
72. Milunsky JM, Maher TA, Michels VV, Milunsky A 2001 Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am J Med Genet 100:311-314
73. Badenhop RF, Cherian S, Lord RS, Baysal BE, Taschner PE, Schofield PR 2001 Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes Cancer 31:255-263
74. Gimenez-Roqueplo AP, Favier J, Rustin P 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621
75. Mariman EC, van Beersum SE, Cremers CW, Struycken PM, Ropers HH 1995 Fine mapping of a putatively imprinted gene for familial non-chromaffin paragangliomas to chromosome 11q13.1: evidence for genetic heterogeneity. Hum Genet 95:56-62
76. Schiavi F, Boedeker CC, Bausch B 2005 Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294:2057-2063
77. Astuti D, Latif F, Dallol 2001 A Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49-54
78. Baysal BE, Rubinstein WS, Taschner PE 2001 Phenotypic dichotomy in mitochondrial complex II genetic disorders. J Mol Med 79:495-503
79. Young AL, Baysal BE, Deb A, Young Jr WF 2002 Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 87:4101-4105
80. Vanharanta S, Buchta M, McWhinney SR 2004 Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74:153-159
81. Neumann HP, Pawlu C, Peczkowska P, Baush B 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951
82. Brauch H, Hoeppner W, Jahnig H 1997 Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 82:4101-4104
83. Eng C, Crossey PA, Mulligan LM 1995 Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32:934-937
84. Bar M, Friedman E, Jakobovitz O 1997 Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin Endocrinol (Oxf) 47:707-712
85. Lindor NM, Honchel R, Khosla S, Thibodeau SN 1995 Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 80:627-629
86. Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF 1997 Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm Res 47:263-268
87. Beldjord C, Desclaux-Arramond F, Raffin-Sanson M 1995 The RET protooncogene in sporadic pheochromocytomas: frequent MEN2-like mutations and new molecular defects. J Clin Endocrinol Metab 80:2063-2068
88. van der Harst E, de Krijger RR, Dinjens WN 1998 Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 77:337-340
89. Benn D, Croxson M, Tucker K, Bambach C, Richardson AL, Delbridge L, Pullan P, Hammond J, Marsh D, Robinson B 2003 Novel succinate dehydrogenase subunit B (SDHB) mutations in familial pheochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic pheochromocytomas. Oncogene 22:1358-1364
90. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C 1994 Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 3:1259-1262
91. Komminoth P, Kunz E, Hiort O 1994 Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing. Am J Pathol 145:922-929
92. Yoshimoto K, Tanaka C, Hamaguchi S 1995 Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type. Endocr J 42:265-270
93. Takaya K, Yoshimasa T, Arai H 1996 The RET proto-oncogene in sporadic pheochromocytomas. Intern Med 35:449-452
94. Lin SR, Yang YC, Tsai JH, Hsu CH 1998 Alterations of RET oncogene in human adrenal tumors. Jpn J Cancer Res 89:634-640
95. Januszewicz A, Neumann HP, Lon I 2000 Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients. J Hypertens 18:1019-1023
96. Neumann HP, Wiestler OD 1991 Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337:1052-1054
97. Neumann HP, Berger DP, Sigmund G 1993 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531-1538
98. Brauch H, Kishida T, Glavac D 1995 Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 95:551-556
99. Elsman P, Alleman MA, Zijlstra F 1998 [Clinical presentations mimicking acute myocardial infarction; therapeutic pitfalls]. Ned Tijdschr Geneeskd 142:1057-1060 (Dutch)
100. Bauters C, Vantyghem MC, Leteurtre E 2003 Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J Med Genet 40:e75
101. Pennisi E 2002 Gene researchers hunt bargains, fixer-uppers. Science 298:735-736
102. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP 2005 Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812-8818